Hormonal
High baseline levels of the hepatokine Selenoprotein P (SeP) are associated with 'exercise resistance,' blunting the beneficial metabolic adaptations to exercise and reducing aerobic capacity in obese individuals.
If you are obese and struggling to lose weight despite exercise, high levels of Selenoprotein P might be blunting your results. The paper suggests you may need longer duration or higher intensity exercise to overcome this 'exercise resistance' and improve your body's ability to use fat for fuel.
In humans, high pre-training levels of SeP were predictive of decreased aerobic exercise capacity, measured as VO2 max... suggesting that FFAs released by VAT lipolysis during and after exercise are less efficiently utilized by SkM and are instead preferentially reincorporated into VAT via VLDL.
Why this rating
Based on a review of animal and human studies, including predictive correlations.
Source
The Role of Exercise in the Interplay between Myokines, Hepatokines, Osteokines, Adipokines, and Modulation of Inflammation for Energy Substrate Redistribution and Fat Mass Loss: A Review
Adrian M. González-Gil et al. · Nutrients · 2020
DOI 10.3390/nu12061899
More from this paper
- Exercise induces the release of myokines (irisin, IL-6, IL-15, METRNL, BAIBA) and hepatokines (FGF21, ANGPTL4, follistatin) which mediate fat mass loss by promoting white adipose tissue (WAT) browning, increasing fatty acid oxidation, and reducing systemic inflammation.Moderate
- Exercise reduces levels of detrimental hepatokines like Fetuin A and Selenoprotein P, which contributes to decreased visceral adipose tissue (VAT) mass and improved insulin sensitivity.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →